Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a Phase II, randomized, placebo-controlled, dose-finding trial - Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)149-150
Number of pages2
JournalInternational Journal of Advances in Rheumatology
Volume9
Issue number4
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Rheumatology

Cite this